Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Medicines, including insulin, to be available in 40 lower-income countries
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Ind-Ra maintains a neutral outlook for healthcare in FY23
An estimated 21 million American women experience BV
Subscribe To Our Newsletter & Stay Updated
